» Articles » PMID: 23349693

Reduction of Splenic Immunosuppressive Cells and Enhancement of Anti-tumor Immunity by Synergy of Fish Oil and Selenium Yeast

Overview
Journal PLoS One
Date 2013 Jan 26
PMID 23349693
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Growing evidence has shown that regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) abnormally increase in cancer cachectic patients. Suppressions of Tregs and MDSCs may enhance anti-tumor immunity for cancer patients. Fish oil and selenium have been known to have many biological activities such as anti-inflammation and anti-oxidation. Whether fish oil and/or selenium have an additional effect on population of immunosuppressive cells in tumor-bearing hosts remained elusive and controversial. To gain insights into their roles on anti-tumor immunity, we studied the fish oil- and/or selenium-mediated tumor suppression and immunity on lung carcinoma, whereof cachexia develops. Advancement of cachexia in a murine lung cancer model manifested with such indicative symptoms as weight loss, chronic inflammation and disturbed immune functionality. The elevation of Tregs and MDSCs in spleens of tumor-bearing mice was positively correlated with tumor burdens. Consumption of either fish oil or selenium had little or no effect on the levels of Tregs and MDSCs. However, consumption of both fish oil and selenium together presented a synergistic effect--the population of Tregs and MDSCs decreased as opposed to increase of anti-tumor immunity when both fish oil and selenium were supplemented simultaneously, whereby losses of body weight and muscle/fat mass were alleviated significantly.

Citing Articles

Supplementation with Fish Oil and Selenium Protects Lipolytic and Thermogenic Depletion of Adipose in Cachectic Mice Treated with an EGFR Inhibitor.

Wang H, Chan Y, Chiu Y, Wu T, Hsia S, Wu C Cells. 2024; 13(17.

PMID: 39273055 PMC: 11394147. DOI: 10.3390/cells13171485.


A Review of Nutraceuticals in Cancer Cachexia.

Caeiro L, Gandhay D, Anderson L, Garcia J Cancers (Basel). 2023; 15(15).

PMID: 37568700 PMC: 10417577. DOI: 10.3390/cancers15153884.


Lung cancer immunotherapy: progress, pitfalls, and promises.

Lahiri A, Maji A, Potdar P, Singh N, Parikh P, Bisht B Mol Cancer. 2023; 22(1):40.

PMID: 36810079 PMC: 9942077. DOI: 10.1186/s12943-023-01740-y.


Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer.

Zhu C, Wang S, Du Y, Dai Y, Huai Q, Li X BMC Gastroenterol. 2022; 22(1):437.

PMID: 36253721 PMC: 9575293. DOI: 10.1186/s12876-022-02532-2.


Fish Oil, Se Yeast, and Micronutrient-Enriched Nutrition as Adjuvant Treatment during Target Therapy in a Murine Model of Lung Cancer.

Wang H, Hsia S, Wu T, Wu C Mar Drugs. 2021; 19(5).

PMID: 34064322 PMC: 8147838. DOI: 10.3390/md19050262.


References
1.
van der Meij B, Langius J, Smit E, Spreeuwenberg M, von Blomberg B, Heijboer A . Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr. 2010; 140(10):1774-80. DOI: 10.3945/jn.110.121202. View

2.
Evans C, Dalgleish A, Kumar D . Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther. 2006; 24(8):1163-77. DOI: 10.1111/j.1365-2036.2006.03075.x. View

3.
Roy M . Effect of selenium on the immunocompetence of patients with head and neck cancer and on adoptive immunotherapy of early and established lesions. Biofactors. 2001; 14(1-4):161-8. DOI: 10.1002/biof.5520140121. View

4.
Beyer M, Schultze J . Regulatory T cells in cancer. Blood. 2006; 108(3):804-11. DOI: 10.1182/blood-2006-02-002774. View

5.
Martin F, Santolaria F, Batista N, Milena A, Gonzalez-Reimers E, Brito M . Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine. 1999; 11(1):80-6. DOI: 10.1006/cyto.1998.0398. View